Overexpression of apoC-I in apoE-null mice: Severe hypertriglyceridemia due to inhibition of hepatic lipase

Journal of Lipid Research

Volumn 43, Issue 12, 2002, Pages 2136-2145

  Conde Knape, Karin ^a   Bensadoun, André ^b   Sobel, Joan H ^a   Cohn, Jeffrey S ^c   Shachter, Neil S ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Lipoproteins; Mutant strains; VLDL

Indexed keywords

APOLIPOPROTEIN C1; APOLIPOPROTEIN E; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; INTERMEDIATE DENSITY LIPOPROTEIN; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; APOLIPOPROTEIN C; LIPID; TRIACYLGLYCEROL LIPASE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; DIET RESTRICTION; DISEASE ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; FEMALE; GENDER; GENE OVEREXPRESSION; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; LIPOLYSIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEX DIFFERENCE; TRANSGENIC MOUSE; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; ARTERIOSCLEROSIS; BIOSYNTHESIS; BLOOD; C57BL MOUSE; DRUG ANTAGONISM; ENZYMOLOGY; GENETICS; HUMAN; LIVER; METABOLISM;

ANIMALS; APOLIPOPROTEIN C-I; APOLIPOPROTEINS C; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; CHOLESTEROL, VLDL; HUMANS; HYPERTRIGLYCERIDEMIA; LIPASE; LIPIDS; LIVER; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC;

EID: 1842855016     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.M200210-JLR200     Document Type: Article

References (68)

1. Windler. E., Y. Chao, and R. J. Havel. 1980. Regulation of the hepatic uptake of triglyceride-rich lipoproteins in the rat. Opposing effects of homologous apolipoprotein E aud individual. C apolipoproteins. J. Biol. Chem 255:8303-8307.
2. Quarfordi, S. H., G. Michalopnlos, and B. Schirmer. 1982. The effect of human C apolipoproteins on the in vitro hepatic metabolism, o£ triglyceride emulsions in the rat. J. Biol. Chem. 257:14642-14647.
3. Kowal, R. C., J. Herz, K. H. Weisgraber, R. W. Mahley, M. S. Brown, and J. L. Goldstein. 1990. Opposing effects of apolipoprotein E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J. Biol. Chem. 265:10771-10779.
4. Weisgraber, K. H., R. W. Mahley, R. C. Kowahl, J. Herz, J. L. Goldstein, and M. S. Brown. 1990. Apolipoprotein C-I modulates the interaction of apolipoprotein E with β-migrating very low density lipoproteins (β-VLDL) and inhibits binding of β-VLDL to low density lipoprotein receptor-related protein. J. Biol. Chem. 265: 22453-22459.
5. Windler, E. E., P. T. Kovanen, Y. S. Chao, M. S. Brown, R. J. Havel, and J. I., Goldstein. 1980. The estradiol-stimulated lipoprotein receptor of rat liver. A binding site that membrane mediates the uptake of rat lipoproteins containing apoproteins B and E. J. Biol. Chem. 255:10464-10471.
6. Schayek, E., and S. Eisenberg. 1991. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J. Biol. Chem. 266:18259-18267.
7. Soutar, A. K., C. W. Garner, H. N. Baker, J. T. Sparrow, R. L. Jackson, A. M. Gotto, Jr., and L. C. Smith. 1975. Effect of the human plasma apolipoproteins and phosphatidylcholine acyl donor on the activity of lecithin: Cholesterol acyl-transferase. Biochemistry 14:3057-3064.
8. Soutar, A. K., G. F. Sigler, L. C. Smith, A. M. Gotto, Jr., and J. T. Sparrow. 1978. Lecithincholesterol acyltransferase activation and lipid binding by synthetic fragments of apolipoprotein C-I. Scand. J. Clin. Lab. Invest. 38: 53-58.
9. Poensgen, J. 1990, Apolipoprotein C-I inhibits thc hydrolysis by phospholipase A2 ol' phospholipids in liposomes and cell membranes. Biochim. Biophys. Acta. 1042: 188-192.
10. Kushwaha, R. S., S. Q. Hasan, H. C, McGill, Jr. G. S. Getz, R. G. Dunham, and P. Kanda. 1993. Charanterizations of cholesteryl ester transfer protein inhibitor from plasma of baboons (Papio sp.) J. Lipid Res. 34: 1288-1297.
11. Gantier, T., D. Masson, J. P. Pais de Barros, A. Athias, P. Gamberi, D. Aunis, M. H. Metz-Boutigue, and Lagrost. 2000. Human apolipoprotein C-I accounts for the ability of plasma high density lipoproteins to inhibit the cholesteryl ester transfer protein activity. Biol. Chem. 275: 37504-37509.
12. Havel, R. J., C. J. Fielding, T. Olivecrona, V. G. Shore, P. E. Fielding, and T. Egelrud. 1973. Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglyccrides by lipoprotein lipase from different sources. Biothemistry. 12: 1828-1833.
13. Kinnunen, P. K. J., and C. Ehnholm. 1976. Effect of serum and c-apoproteins from very low density lipoproteins on human postheparin plasma hepatic lipase. FEBS Lett. 65: 354-357.
14. Simonet, W. S., N. Bucay. R. E. Picas S. J. Lauer. and J. M. Taylor. 1991. Multiple tissue-specific elements control the apolipoprotein E/C-I gene locus in tranagenic mice. J. Biol. Chem. 266: 8651-8694.
15. Jong, M. C., V. E. Dahlmans, P. J. van Gorp, M. L. Breuer, M.J. Mol, A. van der Zee, R. R. Frants, M. H. Holker, and L. M. Havekes. 1996. Both lipolysis and hepatic uptake of VLDL are impaired in transgenic mice coexpresing human apolipoprotein E*3Leiden and human apolipoprotein CI. Arterioscler Thromb. Vasc. Biol. 16: 934-940.
16. Shachter, N. S., Y. Zhu, A. Walsh, J. L. Breslow, and J. D. Smith. 1993. Localization of a liver-specific enhancer in the apolipoprotein E/CI/CII gene locus. J. Lipid Res. 34:1699-1708.
17. Shachter, N. S., T. Ebara, R. Ramakrishnan, G. Steiner, J. L. Breslow, H. N. Ginsberg, and J. D. Smith. 1996. Combined hyperlipidemia in transgenic mice overexpressing human apolipoprotein Cl. J. Clin. Invest. 98:846-855.
18. Jong, M. C., V. E. H. Dahlmans, P. J. J. van Gorp, K. Willems van Dyk, M. L. Breuer, M. H. Hofker, and L. M. Flavekes. 1996. In the absence of the low density lipoprotein receptor, human apolipoprotein C-I overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway. J. Clin. Invest. 98: 2259-2267.
19. Jong, M. C., M. J. Gijbels, V. E. Dahlmans, P. J. Gorp, S. J. Koopman, M. Ponce, M. H. Hofker, and L. M. Havekes. 1998. Hyperlipidemia and cutaneous abnormalities in transgenic mice overexpressing human apolipoprotein Cl. J Clin. Invest. 101: 141-52.
20. Koopmans, S.J., M. C. Jong, I. Que, V. E. H. Dahlmans, H. Pijl, J. K. Radder, M. Frölich, and L. M. Havekes. 2001. Hyperlipidemia is associated with increased insulin mediated glucose metabolism, reduced fatty acid metabolism and normal blood pressure in transgenic mice overexpressing human hyperlipidaemia apolipoproteins Cl. Diabetologia. 44: 437-443.
21. Jong, M. C., K. Willems van Dijk, V. E. Dahlmans, H. van der Boom, K. Kobayashi, K. Oka, G. Siest, L. Chan, M. H. Hofker, and L. M. Havekes. 1999. Reversal of hyperlipidaemia in apolipoprotein CI transgenic mice by adenovirus-mediated gene delivery of the low-density-lipoprotein receptor, but not by the very-low-density-lipoprotein receptor. Biochem. J. 338: 281-287.
22. van Ree. J. H., M. H. Hofker, W. J. J. van den Broek, M. van Deursen, H. van der Boom, R. R. Frants B., Wieringa, and L. M. Havekes. 1995. Increased response to cholesterol feeding in apolipoprotein CI-deficient mice. Biochem. J. 305: 905-911.
23. Ebara, T., R. Ramakrishnan, G. Steiner, and N. S. Shachter. 1997. Chylomicronemia due to apolipoprotein CIII overexpression in apolipoprotein E-null mice. Apolipoprotein CIII-induced hypertryglyceridemia is not mediated by effects on apolipoprotein E. J. Clin. Invest. 99: 2672-2681.
24. Brown, W. V., and M. L. Baginsky. 1972. Inhibition of lipoprotein lipase by an apoprotein or human very Iow density lipoprotein. Biochem. Biophys. Res. Commun. 46: 375-382.
25. Landis, B. A., F. S. Rotolo, W. C. Meyers, A. B. Clark, and S. H. Quarfordt. 1987. Influcnce of apopliprotein E on soluble and heparin-Immobilized hepatic lipase. Am. J. Physiol. 252: G805-G810.
26. Zhang, S. H., R. L. Reddick, J. A. Piedrahita, and N. Maeda. 1992. Spontaneous hypercholosterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258: 468-472.
27. Plump. A. S., J. D. Smith, T. Hayek. K. Aalto-Setälä. A. Walsh J. G. Verstuylft, E. M. Rubin, and J. L. Breslow. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71: 1-20.
28. Cohn,J. S., M. Tremblay, M. Amiot, D. Bouthillier, M. Roy, J. Genest, and J. Davignon. 1996. Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects. Arterioscler. Throb. Vasc. Biol. 16:149-159.
29. Curry, M. D., W., McConathy, J. D. Fesmire, and P. Alanpovic. 1981. Quantitative determination of apolipoproteins C-I and C-II in human plasma by separate electvoimmunoassays. Clin. Chem. 27: 543-548.
30. Havel, R., J., H. A. Eder, and J. H. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34:1345-1353.
31. Lindgren, F. T. L. C. Jensen, and E T. Hatch. 1972. Density-gradient isolations of lipoprotenis. In Blood Lipids and Lipoproteins: Quantitation, Composition and Metabolism. G. J. Nelson, editor. John Wiley and Sons, Inc., New York, NY. 181-274.
32. Ramakrishnan, R., Y. Arad, S. Wong, and H. N. Ginsberg. 1990. Nonuniform radiolabeling of VLDL apolipoprotein B: Implications for the analysis of studies of tile kinetics of the metabolism of lipoproteins containing apolipoprotein B. J. Lipid Res. 31: 1031-1042.
33. Ehnholm, C., R., Kinnunen, J. K. Huttunen E. A. Nikkila, and M. Ohta. 1975. Purification and characterization of lipoprotein lipase from pig myocardium. Biochem J. 149: 649-655.
34. Baginsky, M. I., and W. V. Brown. 1977. Differential characteristics of purified hepatic triglyceride lipase and lipoprotein lipase from purified hepatic triglyceride lipase and lipoprotein lipase from human postheparin plasma. J. Lipid Res. 18: 423-437.
35. Hocquette, J. F., B. Graulet and T. Olivecrona. 1998. Lipoprotein lipase activity and mRNA levels in bovine tissues. Comp. Biochem. Physiol. B Biochem. Mol. Biol. 121: 201-212.
36. Ramsamy T. A., T. A. M. Neville, B. M. Chauhan, D. Aggarwal, and D. L. Sparks. 2000. Apolipoprotein A-1 regulates lipid hydrolysis by hepatic lipase. J. Biol. Chem. 275: 33480-33486.
37. Bensadoun, A., B. Hughes K. Melford, J. Hsu, and D. L. Braesaernle. 1999. Purification of rat hepatic lipase essentially free of apolipoprotein E and apolipoprotein B. Method Mol. Biol. 109: 151-156.
38. de Man, F. H., F. de Beer, A. van der Laarse, A. H. Smelt, and L. M. Havekes. 1997. Lipolysis of very low density lipoproteins by heparan sulfate proteoglycan-hound lipoprotein lipase. J. Lipid Res. 38: 246S-2472.
39. Véniant, M. M., V. Pierotti, D. Newland, G. M. Cham, D. A. Sanan, R. L. Walzem, and S. G. Young. 1997. Susceptibility to atherosclerosis in mice expressing exclusively apolipoprotein B48 or apolipoprotein B100. J. Clin. Invest. 100: 180-188.
40. Barnes, S. E., and P. D. Weinberg. 1998. Contrasting patterns of spontaneous aortic disease in young and old rabbits. Arterioscler. Thromb. Vasc. Biol. 18: 300-308.
41. Ebara, T., K. Conde, Y. Kako, Y. Liu, Y. Xu, R. Ramakrishnan, I. J. Goldherg, and N. S. Shachter. 2000. Delayed catabolism of apoB-48 lipoproteins due to decreased hepara n sulfate proteoglycan production in diabetic mice. Clin. Invest. 10: 1807-1818.
42. Goldberg, I.J., C. A. Scheraldi, L. K. Yacoub, U. Saxena, and C. L. Bisgaier. 1990. Lipoprotein APOC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV. J. Biol. Chem. 265: 4266-4272.
43. Mezdour, H., R. Jone, C. Dengremont, G. Castro, and N. Maeda. 1997. Hepatic lipase deliciency increases plasma cholesterol but reduces susceptibility to atherosclerosis in apolipoprotein E-deficient mice. J. Biol. Chem. 13570-13575.
44. Paigen, B., A. S. Plump, and E. M. Rubin. 1994, The mouse as a model for human cardiovascular disease and hyperlipidemia. Curr. Opin. Lipidol 8: 258-264.
45. Borensztajn, J., T.J. Kotlar, and B. J. McNeill. 1980. Uptake of phospholipid-depleted chylomicrons by the perfused rat liver. Biochem. J. 192: 845-851.
46. Crawford, S. E., and J. Borensztajn. 1999. Plasma clearance and liver uptake of chylomicron remnants generated by hepatic lipase lipolysis: Evidence for a lactoferrin-sensitive and apolipoprotein E-independent pathway. J. Lipid Res. 40: 797-805.
47. Jonas, A. 1975. Self-association of the major protein component of bovine serum high density lipoprotein. Biochim. Biophys. Acta. 393: 471-482.
48. Zhong, S., I.J. Goldherg, C. Bruce, E. Rubin. J. L. Breslow, and A. Tall. 1994. Human APOA-II inhibits the hydrolysis of HDI. triglyceridc and the decrease of HDL size induced hy hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice. J. Clin. Invest. 94: 2457-2467.
49. Boisfer, E., G. Lambert, V. Atger, N. Q. Tran, D. Pastier, C. Benetollo, J-E Trottier I. Beucamps, M. Antonucci, M. Laplaud, S. Griglio, J. Chambaz, and A-D. Kalopissis. 1999. Overexprexsion of human apolipoprotein A-II in mice induces hypertriglyceridemia due to defective very low density lipoprotein hydrolysis. J. Biol. Chem. 27: 11564-11572.
50. Weng, W., N. A. Brandenburg, S. Zhong, J. Halkias, L. Wu, X-C. Jiang, A. Tall, and J. L. Breslow. 1999. ApoA-II maintains HDL levels in part by inhibition of hepatic lipase: Studies in apoA-II and hepatic lipase double knockout mice. J. Lipid Res. 40: 1064-1070.
51. Hime, N.J., P. J. Barter, and K. A. Rye. 1998. The influence of apolipoproteins on the hepatic lipase-mediated hydrolysis of high density lipoprotein phospholipid and triacyglycerol. J. Biol. Chem. 273: 27191-27198.
52. Hedrick, C. C., I. W. Castellani, H. Wong, and A.J. Lusis. 2001. In vivo interactions of apoA-II, apoA-I, and hepatic lipase contributing to HDL structure and antiatherogenic functions. J. Lipid Res. 42: 563-570.
53. Clay, M. A., K. A. Rye, and P.J. Barter. 1990. Evidence in vitro that hepatic lipase reduces the concentration of apolipoprotein A-I in rabbit high-density lipoproteins. Biochim Biophys. Acta. 1044: 50-56.
54. Breckenridge, W. C., J. A. Little P. Alaupovic, C. S. Wang A. Kuksis. G. Kakis, F. Lindgren, and G. Gardiner. 1982. Lipoprotein abnormalities associated with a familial deficiency of hepatic lipase. Atheroslerosis. 45: 161-179.
55. Pihlajamaki, J., I., Karjalainen, P. Karhapaa, I. Vauhkonen, M. R. Taskinen, S. S. Deeb, and M. Laakso. 2000. G-250A substitution in promoter of hepatic lipase gene is associated with dyslipidemia and insulin resistance in healthy control subjects and in members of families with familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 20: 1789-1795.
56. Cohen, J. C., G. L. Vega, and S. M. Grundy. 1999. Hepatic lipase: New insights from genetic and metabolic studies. Curr. Opin. Lipidol. 10: 1159-267.
57. Dugi, K. A., M. J. Amar, C. C. Haudenschild, R. D. Shamburek,A. Bensadoun, R. F. Hoy, Jr., J. Fruchart-Najib, Z. Madj, H. B. Brewer, Jr., and S. Santamarina-Fojo. 2000. In vivo evidence for both lipolytic and nonilpolytlc function of hepatic lipase in the metabolism of HDL, Arterioscler. Thromb. Vasc Biol. 20: 793-800.
58. Homanics, G. E., H. V. de Silva, J. Osada, S. H. Zhang, H. Wong, J. Borensztajn, and N. Maeda. 1995. Mild dyslipidemia in mice following targeted inactivation of the hepatic lipase gene. J. Biol. Chem. 270: 2974-2980.
59. Daggy, B. P., and A. Bensadoun. 1986. Enrichment of apolipoprotein B48 in the LDL density class following in vivo inhibition of hepatic lipase. Biochim. Biophys. Acta. 877: 252-261.
60. Goldberg, I. J., N. A. Le, J. R. Paterniti, H. N. Ginsberg, F. T. Lindgren, and W. V. Brown. 1982. Lipoprotein metabolism during acute inhibition of hepatic triglyceride lipase in the cynomolgus monkey. J. Clin, Invest. 70: 1184-1192.
61. Dichek, H. L., W. Brecht, J. Fan, Z-S. Ji, S. P. A. McCormick, H. Akeefe, I., Conzo, D. A. Sanan, K. H. Weisgraber, S. G. Young, J. M. Taylor, and R. W. Mahley. 1998. Overexpression of hepatic lipase in transgenic mice decreases apolipoprotein B-containing and high density lipoproteins. Evidence that hepatic lipase acts as a ligand for lipoprotein uptake. J. Biol. Chem. 273: 1896-1903.
62. Busch, S. J., R. L. Barnhart, G. A. Martin, M. C. Fitzgerald, M. T. Yates, S.J. Mao, C. E. Thomas, and R. L. Jackson. 1994. Human hepatic triglyceride lipase expression reduces high density lipoprotein and aortic cholesterol in cholesterol-fed transgenic mice. J. Biol. Chem. 269: 16376-16382.
63. Chang, S., and J. Borensztajn. 1995. Uptake of chylomicron remnants and hepatic lipase-treated chylomicrons by a non-transformed murine hepatocyte cell line in culture. Biochim Biophys. Acta. 1256: 81-87.
64. Ji, Z. S., H. J. Lauer, A. Fazio, A. Bensadoun, J. M. Taylor, and R. W. Mahley. 1994. Enhanced binding and uptake of remnant lipoproteins by hepatic lipase-secreting hepatoma cells in culture. J. Biol. Chem 269: 13429-13436.
65. Ji, Z. S., H. L. Dichek, R. D. Miranda, and R. W. Mahley, 1997. Heparan sulfate proteoglycans participate in hepatic lipase and apolipoprotein E-mediated binding and uptake of plasma lipoproteins, including high density lipoproteins. J. Biol. Chem. 272: 31285-31292.
66. de Faria, E., L. G. Fong, M. Komaromy and A. D. Cooper. 1996. Relative roles of the LDL receptor, the LDL receptor-like protein, and hepatic lipase in chylomicron remnant removal by the liver. J. Lipid Res. 37: 197-209.
67. Santamarina-Fojo, S., and C. Haudenachild. 2000. Role of hepatic and lipoprotein lipase in lipoprotein metabolism and atherosclerosis: Studies in transgenic and knockout animal models and somatic gene transfer. Int. J. Tissue React. 22: 39-47.
68. Yu, K. C., and A. D. Cooper. 2001. Postprandial lipoproteins and atherosclerosis. Front. Biosci. 6: D332-D354.